Back to Resource Hub White paper

DHTs in Clinical Trials: Key Points From the FDA's Draft Guidance

Signant's Bill Byrom offers expert analysis of the FDA's draft guidance on Digital Health Technologies (DHTs) in clinical trials. Explore critical regulatory considerations that will shape how sponsors implement wearables, sensors, and mobile devices in clinical research.

The paper also clarifies key validation requirements, BYOD considerations, and data integrity safeguards needed for regulatory submission. Particularly valuable are the practical recommendations on managing software updates, minimizing missing data, and demonstrating measurement accuracy.

Whether you're exploring decentralized trial models or selecting appropriate technologies for specific patient populations, this guide aligns FDA expectations with established industry consensus from DiMe, DIA, and C-Path ePRO Consortium.

Download our whitepaper to ensure your DHT implementation meets FDA expectations for your next clinical trial.

Similar posts

Looking for more insights? Explore related resources.

ARTICLE

PROs and ObsROs in Pediatric Clinical Trials: Measure Selection and Implementation

READ THE ARTICLE
WHITE PAPER

Takeaways and Perspectives: FDA Draft Guidance on DCTs

READ THE PAPER
BLOG POST

PROs in Medical Device Trials - Lessons From the FDA Guidance

VISIT THE BLOG

Get notified on new marketing insights

Here mention the benefits of subscribing